Research Papers:
NYESO1 antigen expression and immune response are associated with poor prognosis in MAGEA4vaccinated patients with esophageal or head/neck squamous cell carcinoma
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 2548 views | Full Text 3727 views
Shugo Ueda1, Yoshihiro Miyahara2, Yasuhiro Nagata3, Eiichi Sato4, Taizo Shiraishi5, Naozumi Harada6, Hiroaki Ikeda7, Hiroshi Shiku8 and Shinichi Kageyama9
1Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Kita-ku, Osaka 530-8480, Japan
2Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
3Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan
4Department of Pathology, Institute of Medical Science, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan
5Department of Oncologic Pathology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
6United Immunity, Co., Ltd., Tsu, Mie 514-8507, Japan
7Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan
8Departments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
9Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
Correspondence to:
Shugo Ueda, email: [email protected]
Shinichi Kageyama, email: [email protected]
Keywords: cancer vaccine; MAGE-A4; NY-ESO-1; immune response; esophageal cancer
Received: July 27, 2018 Accepted: October 25, 2018 Published: November 13, 2018
ABSTRACT
MAGE-A4 antigen is a cancer-testis antigen that is frequently expressed in tumor tissues. Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received a CHP-MAGE-A4 vaccine. Twenty-two patients with advanced or metastatic cancer were enrolled, and were subcutaneously vaccinated with either 100 μg or 300 μg of CHP-MAGE-A4. Seven and 15 patients, respectively, were repeatedly vaccinated with 100 μg or 300 μg of CHP-MAGE-A4; patients in both groups received a median of 7 doses. No serious adverse events related to the vaccine were observed. Of 7 patients receiving the 100 μg dose, 2 (29%) showed immune responses, compared with 3 of the 14 (21%) patients who received the 300 μg dose. In total, MAGE-A4-specific antibody responses were induced in 5 of 21 (24%) patients. No differences in survival were seen between patients receiving the 100 μg and 300 μg doses, or between immune responders and non-responders. Eleven (50%) patients had pre-existing antibodies to NY-ESO-1. In 16 patients with esophageal or head/neck squamous cell carcinoma, the survival time was significantly shorter in those who had NY-ESO-1-co-expressing tumors. Patients with high pre-existing antibody responses to NY-ESO-1 displayed worse prognosis than those with no pre-existing response. Therefore, in planning clinical trials of MAGE-A4 vaccine, enrolling NY-ESO-1-expressing tumor or not would be a critical issue to be discussed. Combination vaccines of MAGE-A4 and NY-ESO-1 antigens would be one of the strategies to overcome the poor prognosis.